Table 2.

Main characteristics and outcomes of the ARMOR1 and ARMOR2 clinical trials

	ARMOR169	ARMOR2, part 169	ARMOR2, parts 1 and 2 (combined study)70
Number of patients	49	28	107
Metastatic disease (M)	51%	86%	77%
Abi-R or Enz-R patients	No	Abi-R: three patients	Abi-R: 37 patients Enz-R: nine patients
Drug formulation	Capsules	SDD tablets	SDD tablets
Food effect	Yes	No	No
Dose range	650 mg	1,700 mg	2,550 mg
	975 mg	2,550 mg
	1,300 mg	3,400 mg
	1,950 mg
	2,600 mg
PSA decline ≥30%	49%	64%	83%a
PSA50	22.4%	48%	70%a

Note:

^aPSA decline results in the M₀ and M₁ treatment-naïve cohorts.

Abbreviations: Abi-R, abiraterone refractory; Enz-R, enzalutamide refractory; SDD, spray dry dispersion; PSA₅₀, PSA decline ≥50%.